Insmed Incorporated

INSM

$11.00B

Large Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaBRIDGEWATER1.3K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 14, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 0 past

⭐Phase 3Next

Treprostinil Palmitil Inhalation Powder Phase 3 Results Expected

Mar 14, 2026Treprostinil Palmitil Inhalation Powder31

Primary completion for Treprostinil Palmitil Inhalation Powder trial (NCT05649722) in Pulmonary Hypertension

Source

🎯PDUFA

FDA PDUFA Date Arikayce (priority)

4/28/2026

For NTM lung disease. sNDA filing. Extracted from SEC filing: 8-K

Source

Phase 2

Brensocatib Phase 2 Results Expected

May 22, 2026Brensocatib214

Primary completion for Brensocatib trial (NCT06685835) in Hidradenitis Suppurativa

Source

⭐Phase 3

Treprostinil Palmitil Phase 3 Results Expected

Dec 31, 2026Treprostinil Palmitil91

Primary completion for Treprostinil Palmitil trial (NCT05649748) in Pulmonary Arterial Hypertension

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Liposomal amikacin for inhalation

Phase 3

Cystic Fibrosis

Treprostinil Palmitil

Phase 3

Pulmonary Hypertension

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.

Phase 3

Pseudomonas Aeruginosa Infection

ALIS

Phase 3

Mycobacterium Infections, Nontuberculous

Azithromycin

Phase 3

Mycobacterium Infections, Nontuberculous

LAI (Liposomal Amikacin for Inhalation) 590 mg

Phase 3

Mycobacterium Infections, Nontuberculous

Brensocatib 10 mg

Phase 3

Non-Cystic Fibrosis Bronchiectasis

rhIGF-I/rhIGFBP-3

Phase 3

Myotonic Dystrophy Type 1

Treprostinil Palmitil Inhalation Powder

Phase 3

Pulmonary Hypertension

Brensocatib 25 mg

Phase 3

Non-Cystic Fibrosis Bronchiectasis

LAI 590 mg

Phase 3

NTM Lung Infection Due to MAC

ARIKACE™

Phase 2

Cystic Fibrosis

Cisplatin liposomal

Phase 2

Osteosarcoma Metastatic

Arikayce™ 560 mg

Phase 2

Cystic Fibrosis

Mometasone furoate nasal spray (MFNS)

Phase 2

Chronic Rhinosinusitis Without Nasal Polyps

280 mg Arikayce™

Phase 2

Bronchiectasis

Liposomal amikacin for inhalation (LAI)

Phase 2

Mycobacterium Infections, Nontuberculous

Brensocatib

Phase 2

Hidradenitis Suppurativa

Arikayce™

Phase 2

Cystic Fibrosis

Drug Name	Phase	Indication	Designations
Liposomal amikacin for inhalation	Phase 3	Cystic Fibrosis	-
Treprostinil Palmitil	Phase 3	Pulmonary Hypertension	-
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.	Phase 3	Pseudomonas Aeruginosa Infection	-
ALIS	Phase 3	Mycobacterium Infections, Nontuberculous	-
Azithromycin	Phase 3	Mycobacterium Infections, Nontuberculous	-
LAI (Liposomal Amikacin for Inhalation) 590 mg	Phase 3	Mycobacterium Infections, Nontuberculous	-
Brensocatib 10 mg	Phase 3	Non-Cystic Fibrosis Bronchiectasis	-
rhIGF-I/rhIGFBP-3	Phase 3	Myotonic Dystrophy Type 1	-
Treprostinil Palmitil Inhalation Powder	Phase 3	Pulmonary Hypertension	-
Brensocatib 25 mg	Phase 3	Non-Cystic Fibrosis Bronchiectasis	-
LAI 590 mg	Phase 3	NTM Lung Infection Due to MAC	-
ARIKACE™	Phase 2	Cystic Fibrosis	-
Cisplatin liposomal	Phase 2	Osteosarcoma Metastatic	-
Arikayce™ 560 mg	Phase 2	Cystic Fibrosis	-
Mometasone furoate nasal spray (MFNS)	Phase 2	Chronic Rhinosinusitis Without Nasal Polyps	-
280 mg Arikayce™	Phase 2	Bronchiectasis	-
Liposomal amikacin for inhalation (LAI)	Phase 2	Mycobacterium Infections, Nontuberculous	-
Brensocatib	Phase 2	Hidradenitis Suppurativa	-
Arikayce™	Phase 2	Cystic Fibrosis	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

INSM News